The impact of COVID-19 disruption to cervical cancer screening in England on excess diagnoses

Alejandra Castanon, Rebolj M Matejka, Francesca Pesola, Peter Sasieni
doi: https://doi.org/10.1101/2020.11.30.20240754

Article Information

doi 
https://doi.org/10.1101/2020.11.30.20240754
History 
  • November 30, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Alejandra Castanon1,*,
  2. Rebolj M Matejka1,a,
  3. Francesca Pesola1,a and
  4. Peter Sasieni1
  1. 1King’s College London, Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences
  1. ↵* Corresponding author; email: alejandra.castanon{at}kcl.ac.uk

  1. ↵a Contributed equally

Back to top
Posted November 30, 2020.
Download PDF

Supplementary Material

Data/Code
Email
The impact of COVID-19 disruption to cervical cancer screening in England on excess diagnoses
Alejandra Castanon, Rebolj M Matejka, Francesca Pesola, Peter Sasieni
medRxiv 2020.11.30.20240754; doi: https://doi.org/10.1101/2020.11.30.20240754
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area